These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30607513)

  • 1. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.
    Xu Z; Hu P; Fang D; Ni L; Xu J
    J Mol Model; 2019 Jan; 25(1):13. PubMed ID: 30607513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
    Bahcall M; Sim T; Paweletz CP; Patel JD; Alden RS; Kuang Y; Sacher AG; Kim ND; Lydon CA; Awad MM; Jaklitsch MT; Sholl LM; Jänne PA; Oxnard GR
    Cancer Discov; 2016 Dec; 6(12):1334-1341. PubMed ID: 27694386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
    Liu T; Wang Z; Guo P; Ding N
    Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
    Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
    J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.
    Wang Z; Jiang M; Feng N; Li C
    Biochimie; 2018 Sep; 152():188-197. PubMed ID: 30017898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
    Ding X; Liu X; Song X; Yao J
    Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
    Wang CG; Zeng DX; Huang JA; Jiang JH
    Medicine (Baltimore); 2018 Jan; 97(1):e9021. PubMed ID: 29505507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on treatment of MET signaling pathway in non-small cell lung cancer.
    Yu X; Yu S; Fan Y
    Int J Clin Oncol; 2020 Aug; 25(8):1450-1458. PubMed ID: 32440811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.
    Funakoshi Y; Mukohara T; Ekyalongo RC; Tomioka H; Kataoka Y; Shimono Y; Chayahara N; Toyoda M; Kiyota N; Fujiwara Y; Minami H
    Oncol Res; 2013; 21(6):287-93. PubMed ID: 25198658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
    Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
    Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
    Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
    Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
    Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
    Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
    Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
    Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.